Allergy Therapeutics plc (LON:AGY - Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as GBX 6.50 ($0.08) and last traded at GBX 6.40 ($0.08), with a volume of 91787 shares trading hands. The stock had previously closed at GBX 6.40 ($0.08).
Allergy Therapeutics Stock Performance
The firm has a fifty day simple moving average of GBX 5.23 and a 200-day simple moving average of GBX 4.96. The company has a quick ratio of 1.48, a current ratio of 1.40 and a debt-to-equity ratio of 37.22. The company has a market cap of £305.28 million, a PE ratio of -106.67, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
(
Get Free Report)
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Featured Articles
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
